The mission of biopharma companies to bring effective new therapies to patients to solve unmet medical needs has become much harder these days. Not only has the cost to accomplish those goals jumped significantly, but the prices being set – in large part to recover the R&D investments – are being questioned by politicos, regulators and patients alike who view some of the price points as unjustifiable.